Associated Papers
A prospective, multicenter, comprehensive genomic profile signature study in patients with EGFR-mutant advanced non-small cell lung cancer at the first-line treatment failure of osimertinib.
Shi Y et al.
Signal Transduction and Targeted Therapy, 2025
Epidermal Growth Factor Mutation Analysis in Patients With Bronchogenic Adenocarcinoma: Prevalence and Clinical Profile-Outlook From a Tertiary Care Center in India.
T J G et al.
Cureus, 2025
Inflammatory Giant Cell Carcinoma of the Lung: Clinicopathologic, Immunohistochemical, and Next-generation Sequencing Study of 14 Cases.
Suster DI et al.
The American Journal of Surgical Pathology, 2024
The Advantage of Targeted Next-Generation Sequencing over qPCR in Testing for Druggable EGFR Variants in Non-Small-Cell Lung Cancer.
Szpechcinski A et al.
International Journal of Molecular Sciences, 2024
Genomic features of lung cancer patients in Indonesia's national cancer center.
Hanafi AR et al.
Bmc Pulmonary Medicine, 2024
The treatment of patients with non-small cell lung cancer carrying uncommon EGFR mutations, HER2 mutations, or brain metastases: a systematic review of pre-clinical and clinical findings for dacomitinib.
Yang LL et al.
Translational Cancer Research, 2023
ERBB2 mutation landscape in non-small cell lung cancer patients in Northeast China.
Li H et al.
Tumori, 2023
A Primary Lung and Breast Cancer Patient with Germline EGFR R776H Mutation: A Case Report and Literature Review.
Li D et al.
Oncotargets and Therapy, 2023
Comprehensive analyses of genomic features and mutational signatures in adenosquamous carcinoma of the lung.
Wang H et al.
Frontiers in Oncology, 2022
A Nationwide Study on the Impact of Routine Testing for EGFR Mutations in Advanced NSCLC Reveals Distinct Survival Patterns Based on EGFR Mutation Subclasses.
Koopman B et al.
Cancers, 2021
EGFR Exon 18 Mutations in Advanced Non-Small Cell Lung Cancer: A Real-World Study on Diverse Treatment Patterns and Clinical Outcomes.
Xu H et al.
Frontiers in Oncology, 2021
Identification of the Unique Clinical and Genetic Features of Chinese Lung Cancer Patients With EGFR Germline Mutations in a Large-Scale Retrospective Study.
Lin X et al.
Frontiers in Oncology, 2021
Spectrum of driver mutations and clinical impact of circulating tumor DNA analysis in non-small cell lung cancer: Analysis of over 8000 cases.
Mack PC et al.
Cancer, 2020
Genome analysis of peeling archival cytology samples detects driver mutations in lung cancer.
Kunimasa K et al.
Cancer Medicine, 2020
Genetic alterations in epidermal growth factor receptor-tyrosine kinase inhibitor-naïve non-small cell lung carcinoma.
Yamaura T et al.
Oncology Letters, 2020
Clinical Characteristics and Outcomes of Non-small Cell Lung Cancer Patients with HER2 Alterations in Korea.
Lee K et al.
Cancer Research and Treatment, 2020
Identifying a wide range of actionable variants using capture-based ultra-deep targeted sequencing in treatment-naive patients with primary lung adenocarcinoma.
Chen L et al.
International Journal of Clinical and Experimental Pathology, 2020
Comparison of next-generation sequencing and immunohistochemistry analysis for targeted therapy-related genomic status in lung cancer patients.
Nong L et al.
Journal of Thoracic Disease, 2019
Genomic Signature of Driver Genes Identified by Target Next-Generation Sequencing in Chinese Non-Small Cell Lung Cancer.
Wen S et al.
The Oncologist, 2019
Epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors in non-small cell lung cancer harboring uncommon EGFR mutations: Focus on afatinib.
Masood A et al.
Seminars in Oncology, 2019
Heterogeneous Responses to Epidermal Growth Factor Receptor (EGFR) Tyrosine Kinase Inhibitors (TKIs) in Patients with Uncommon EGFR Mutations: New Insights and Future Perspectives in this Complex Clinical Scenario.
Russo A et al.
International Journal of Molecular Sciences, 2019
Oncogenic driver mutations in Swiss never smoker patients with lung adenocarcinoma and correlation with clinicopathologic characteristics and outcome.
Grosse C et al.
Plos One, 2019
Efficacy and safety analysis of the German expanded access program of osimertinib in patients with advanced, T790M-positive non-small cell lung cancer.
Stratmann JA et al.
Journal of Cancer Research and Clinical Oncology, 2018
Epidermal Growth Factor Receptor (EGFR) Kinase Inhibitors and Non-Small Cell Lung Cancer (NSCLC) - Advances in Molecular Diagnostic Techniques to Facilitate Targeted Therapy.
Ghafoor Q et al.
Pathology Oncology Research : Por, 2018
Idylla assay and next generation sequencing: an integrated EGFR mutational testing algorithm.
De Luca C et al.
Journal of Clinical Pathology, 2018
Targeted sequencing reveals distinct pathogenic variants in Chinese patients with lung adenocarcinoma brain metastases.
Ma Y et al.
Oncology Letters, 2018
Clinical mutational profiling of 1006 lung cancers by next generation sequencing.
Illei PB et al.
Oncotarget, 2017
Next-generation sequencing reveals novel resistance mechanisms and molecular heterogeneity in EGFR-mutant non-small cell lung cancer with acquired resistance to EGFR-TKIs.
Lee CK et al.
Lung Cancer (amsterdam, Netherlands), 2017
Mutations of the Epidermal Growth Factor Receptor Gene in Triple-Negative Breast Cancer.
Kim A et al.
Journal of Breast Cancer, 2017
Identification and Functional Characterization of EGFR V769M, a Novel Germline Variant Associated With Multiple Lung Adenocarcinomas.
Hellmann MD et al.
Jco Precision Oncology, 2017
Profile of the therascreen® EGFR RGQ PCR kit as a companion diagnostic for gefitinib in non-small cell lung cancer.
Hsiue EH et al.
Expert Review of Molecular Diagnostics, 2016
Case report: Durable response to afatinib in a patient with lung cancer harboring two uncommon mutations of EGFR and a KRAS mutation.
Tanizaki J et al.
Lung Cancer (amsterdam, Netherlands), 2016
Not all epidermal growth factor receptor mutations in lung cancer are created equal: Perspectives for individualized treatment strategy.
Kobayashi Y et al.
Cancer Science, 2016
Protein-structure-guided discovery of functional mutations across 19 cancer types.
Niu B et al.
Nature Genetics, 2016
Management of advanced non-small cell lung cancers with known mutations or rearrangements: latest evidence and treatment approaches.
Shea M et al.
Therapeutic Advances in Respiratory Disease, 2016
EGFR Exon 18 Mutations in Lung Cancer: Molecular Predictors of Augmented Sensitivity to Afatinib or Neratinib as Compared with First- or Third-Generation TKIs.
Kobayashi Y et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research, 2015
Afatinib in Non-Small Cell Lung Cancer Harboring Uncommon EGFR Mutations Pretreated With Reversible EGFR Inhibitors.
Heigener DF et al.
The Oncologist, 2015
Common Oncogene Mutations and Novel SND1-BRAF Transcript Fusion in Lung Adenocarcinoma from Never Smokers.
Jang JS et al.
Scientific Reports, 2015
High EGFR gene copy number predicts poor outcome in triple-negative breast cancer.
Park HS et al.
Modern Pathology : an Official Journal of the United States and Canadian Academy of Pathology, Inc, 2014
Potentially functional SNPs (pfSNPs) as novel genomic predictors of 5-FU response in metastatic colorectal cancer patients.
Wang J et al.
Plos One, 2014
Molecular diagnostic algorithm for epidermal growth factor receptor mutation detection in Asian lung adenocarcinomas: comprehensive analyses of 445 Taiwanese patients with immunohistochemistry, PCR-direct sequencing and Scorpion/ARMS methods.
Ho HL et al.
Respirology (carlton, Vic.), 2013
Small-cell carcinoma in the setting of pulmonary adenocarcinoma: new insights in the era of molecular pathology.
Norkowski E et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer, 2013
Sensitivity and kinase activity of epidermal growth factor receptor (EGFR) exon 19 and others to EGFR-tyrosine kinase inhibitors.
Furuyama K et al.
Cancer Science, 2013
Analytic performance studies and clinical reproducibility of a real-time PCR assay for the detection of epidermal growth factor receptor gene mutations in formalin-fixed paraffin-embedded tissue specimens of non-small cell lung cancer.
O'Donnell P et al.
Bmc Cancer, 2013
DNA-Mutation Inventory to Refine and Enhance Cancer Treatment (DIRECT): a catalog of clinically relevant cancer mutations to enable genome-directed anticancer therapy.
Yeh P et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research, 2013
Patterns of DNA mutations and ALK rearrangement in resected node negative lung adenocarcinoma.
Yip PY et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer, 2013
Epidermal growth factor receptor mutations in non-small cell lung cancer influence downstream Akt, MAPK and Stat3 signaling.
Zimmer S et al.
Journal of Cancer Research and Clinical Oncology, 2009
Applications of computational tools to predict functional SNPs effects in human ErbB genes.
Choura M et al.
Journal of Receptor and Signal Transduction Research, 2009
Good response to gefitinib in lung adenocarcinoma of complex epidermal growth factor receptor (EGFR) mutations with the classical mutation pattern.
Wu SG et al.
The Oncologist, 2008
The impact of epidermal growth factor receptor gene status on gefitinib-treated Japanese patients with non-small-cell lung cancer.
Ichihara S et al.
International Journal of Cancer, 2007